Article Text

AB1043 Etanercept Retention Rates in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
  1. C.V. Dongen1,
  2. E. Kneepkens1,
  3. E. Vogelzang1,
  4. M. l'Ami1,
  5. C. Krieckaert1,
  6. I. van der Horst1,2,
  7. A. Voskuyl2,
  8. M. Nurmohamed1,3
  1. 1Research and Education, Reade
  2. 2Rheumatology
  3. 3Internal Medicine, VUmc, Amsterdam, Netherlands


Background Anti-TNF therapy with etanercept is, according to clinical trials, effective in approximately 60 - 70% of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA). However, some patients experience adverse events or do not respond to therapy with these drugs leading to a shorter retention.

Objectives To evaluate and compare retention rates of etanercept in patients with RA, AS or PsA treated with etanercept.

Methods A total of 606 patients with RA, 230 patients with AS and 157 patients with PsA were consecutively included in observational cohorts. CRP, BSE (RA, AS, PSA), DAS28 (RA, PSA), BASFI and BASDAI (AS) were collected during follow-up. Data with respect to moment and reason of dropout were collected.

Results Five year follow-up data was available for 350 patients with RA, 180 patients with AS and 108 patients with PsA. The proportion of patients with RA that was still on drug at five years (25%) was significantly (p<0.05) lower than that of patients with AS (43%) and PSA (41%). Disease activity improved significantly (p<0.05) compared to baseline, at six months and remained stable thereafter up to five years, in all three disease.

Conclusions Disease activity in etanercept treated patients with RA, AS or PsA improved significantly at six months and stabilizes thereafter. The five year retention rate is the highest (>40%) in patients with AS and PSA, whereas only 25% of patients with RA is still on drug five years after start of therapy.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.5199

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.